Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPO1 | O14980 | 2/20 | 0.40 |
| ▸ | PARP1 | P09874 | 6/20 | 0.38 |
| ▸ | JAK2 | O60674 | 4/20 | 0.36 |
| ▸ | JAK1 | P23458 | 3/20 | 0.36 |
| ▸ | TYK2 | P29597 | 3/20 | 0.36 |
| ▸ | JAK3 | P52333 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 4/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3990548 | 0.83 | XPO1 (0.41) | XPO1JAK2JAK3SMN1; SMN2 | |
| SCHEMBL3987691 | 0.76 | XPO1 (0.40) | XPO1PARP1JAK2JAK1TYK2 | |
| SCHEMBL3984929 | 0.76 | XPO1 (0.39) | XPO1JAK2TYK2PIM1PIM2 | |
| SCHEMBL3992045 | 0.71 | XPO1 (0.46) | XPO1SMN1; SMN2PIM1PIM2NPC1 | |
| SCHEMBL1702768 | 0.71 | DHODH (0.57) | SMN1; SMN2NPC1RAB9A | |
| SCHEMBL1702172 | 0.71 | DHODH (0.46) | XPO1SMN1; SMN2RAB9A | |
| SCHEMBL16388912 | 0.70 | DHODH (0.47) | XPO1PARP1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL14820779 | 0.70 | RAB9A (0.44) | JAK2JAK1TYK2JAK3SMN1; SMN2 | |
| SCHEMBL24687325 | 0.70 | DHODH (0.42) | XPO1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL14808817 | 0.69 | ZAP70 (0.45) | JAK2JAK1TYK2JAK3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521560-B2 | 2-substituted quinoline compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521560-B2 | 2-substituted quinoline compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521560-B2 | 2-substituted quinoline compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| EP-1781637-A1 | 2-SUBSTITUTED QUINOLINE COMPOUNDS AND THEIR USES AS INHIBITORS OF THE IGE RECEPTOR SIGNALING CASCADE | Rigel Pharmaceuticals, Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20060040982-A1 | 2-Substituted quinoline compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2006-02-23 | — | — | US | disclosed |
| WO-2006004865-A1 | 2-SUBSTITUTED QUINOLINE COMPOUNDS AND THEIR USES AS INHIBITORS OF THE IGE RECEPTOR SIGNALING CASCADE | RIGEL PHARMACEUTICALS, INC. (US) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040982-A1 | 2-Substituted quinoline compounds and their uses | FCER2, LTB4R2, CYSLTR2 | XPO1 2363/4885PARP1 821/4885JAK2 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.